Elin Rowen

1.7k total citations
12 papers, 141 citations indexed

About

Elin Rowen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elin Rowen has authored 12 papers receiving a total of 141 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elin Rowen's work include Cancer Treatment and Pharmacology (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Elin Rowen is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Elin Rowen collaborates with scholars based in United States. Elin Rowen's co-authors include Nikolai A. Podoltsev, Mark S. Rubin, Robert O. Kerr, José A. Figueroa, Muhammad Wasif Saif, Amit Mahajan, Anne C. Chiang, Heather Gerrish, Roy S. Herbst and Veronica Chiang and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics and Journal of Thoracic Oncology.

In The Last Decade

Elin Rowen

11 papers receiving 141 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elin Rowen United States	5	98	59	43	23	20	12	141
Susan Wróblewski United States	8	54 0.6×	23 0.4×	28 0.7×	82 3.6×	21 1.1×	19	150
Maya Kostova United States	7	39 0.4×	27 0.5×	27 0.6×	62 2.7×	14 0.7×	10	146
Donglei Zhu China	6	59 0.6×	53 0.9×	31 0.7×	38 1.7×	36 1.8×	7	151
Jielin Wei China	8	50 0.5×	49 0.8×	31 0.7×	48 2.1×	81 4.0×	13	199
Neelesh Sharma United States	7	82 0.8×	74 1.3×	56 1.3×	86 3.7×	36 1.8×	16	196
Asaad Trabolsi United States	8	147 1.5×	25 0.4×	16 0.4×	42 1.8×	25 1.3×	19	204
Nick Knudsen United States	7	194 2.0×	35 0.6×	13 0.3×	94 4.1×	24 1.2×	12	286
Sara Bastian Switzerland	6	118 1.2×	34 0.6×	12 0.3×	44 1.9×	14 0.7×	18	163
C. Rees United Kingdom	4	90 0.9×	43 0.7×	26 0.6×	60 2.6×	20 1.0×	7	151
Michel Vulfovich United States	6	59 0.6×	14 0.2×	16 0.4×	54 2.3×	18 0.9×	9	145

Countries citing papers authored by Elin Rowen

Since Specialization

Citations

This map shows the geographic impact of Elin Rowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elin Rowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elin Rowen more than expected).

Fields of papers citing papers by Elin Rowen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elin Rowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elin Rowen. The network helps show where Elin Rowen may publish in the future.

Co-authorship network of co-authors of Elin Rowen

This figure shows the co-authorship network connecting the top 25 collaborators of Elin Rowen. A scholar is included among the top collaborators of Elin Rowen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elin Rowen. Elin Rowen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Gettinger, Scott, Frederick H. Wilson, Sarah B. Goldberg, et al.. (2023). Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.. Journal of Clinical Oncology. 41(16_suppl). 9121–9121. 1 indexed citations

Gettinger, Scott, Sarah B. Goldberg, Anne C. Chiang, et al.. (2023). MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal of Thoracic Oncology. 18(11). S155–S155. 1 indexed citations

Goldberg, Sarah B., Scott Gettinger, Amit Mahajan, et al.. (2018). Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.. Journal of Clinical Oncology. 36(15_suppl). 2009–2009. 28 indexed citations

Goldberg, Sarah B., Scott Gettinger, Amit Mahajan, et al.. (2015). Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.. Journal of Clinical Oncology. 33(15_suppl). 8035–8035. 29 indexed citations

Mehnert, Janice M., Amir Mortazavi, Mark N. Stein, et al.. (2011). A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.. Journal of Clinical Oncology. 29(7_suppl). 278–278. 2 indexed citations

Gibney, Geoffrey T., Aymen Elfiky, Christopher Hoimes, et al.. (2010). Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.. Journal of Clinical Oncology. 28(15_suppl). TPS244–TPS244.

Gibney, Geoffrey T., Aymen Elfiky, Scott Bussom, et al.. (2010). A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes.. Journal of Clinical Oncology. 28(15_suppl). 4661–4661. 4 indexed citations

Saif, Muhammad Wasif, Nikolai A. Podoltsev, Mark S. Rubin, et al.. (2009). Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation. 28(2). 186–194. 64 indexed citations

Saif, Muhammad Wasif, Nikolai A. Podoltsev, Mark A. Rubin, et al.. (2009). Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation. 1–1. 8 indexed citations

10.

Deshpande, Hari A., Scott Gettinger, Elin Rowen, et al.. (2009). A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). e13501–e13501. 1 indexed citations

11.

Molife, R., James Lee, Daniel Petrylak, et al.. (2007). A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 2 indexed citations

12.

Burtness, Barbara, Michael K. Gibson, Jill Lacy, et al.. (2005). Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal of Clinical Oncology. 23(16_suppl). 4070–4070. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact